RecruitingNot ApplicableNCT05489588

The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study

Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Iliofemoral Venous Obstruction


Sponsor

W.L.Gore & Associates

Enrollment

165 participants

Start Date

Mar 2, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

This study is a prospective, non-randomized, multicenter, single-arm, clinical study to evaluate the performance, safety and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic iliofemoral venous obstruction.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called GORE® VIAFORT Vascular Stent for people with vein disease, vein occlusion, and other related conditions. The study is currently recruiting participants at 27 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEGORE® VIAFORT Vascular Stent

Treatment of unilateral symptomatic iliofemoral venous obstruction with the GORE® VIAFORT Vascular Stent.


Locations(27)

Stanford University School of Medicine

Stanford, California, United States

Advanced Heart and Vein (ClinRe)

Thornton, Colorado, United States

Vascular Care Group

Darien, Connecticut, United States

Yale University

New Haven, Connecticut, United States

MedStar Washington Hospital Center

Washington D.C., District of Columbia, United States

Manatee Memorial Hospital

Bradenton, Florida, United States

Northwestern University

Chicago, Illinois, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Vascular Care Group

Wellesley, Massachusetts, United States

University of Michigan Hospital

Ann Arbor, Michigan, United States

Englewood Hospital & Med Center

Englewood, New Jersey, United States

Holy Name Medical Center

Teaneck, New Jersey, United States

Mount Sinai Medical Center

New York, New York, United States

Stony Brook

Stony Brook, New York, United States

St. Peter's Vascular Associates

Troy, New York, United States

University of North Carolina - Chapel Hill

Chapel Hill, North Carolina, United States

Atrium Health-Sanger Heart and Vascular Institute

Charlotte, North Carolina, United States

NC Heart and Vascular Research

Raleigh, North Carolina, United States

Bethesda North

Cincinnati, Ohio, United States

University Hospitals Cleveland

Cleveland, Ohio, United States

Cleveland Clinic Foundation

Cleveland, Ohio, United States

University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, United States

The Miriam Hospital

Providence, Rhode Island, United States

UT Southwestern

Dallas, Texas, United States

Sentara General Hospital

Norfolk, Virginia, United States

Overlake Hospital

Bellevue, Washington, United States

Medical College of Wisconsin - Froedtert Hospital

Milwaukee, Wisconsin, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05489588


Related Trials